Skip to main content

Duke Cancer Institute

DCI Blog
Events
DCI Members
Contact
Give

Cancer Types

All Cancers
Primary Brain Cancer
Brain and Spine Metastasis
Breast Cancer
Endocrine Neoplasia
Gastrointestinal Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematologic Malignancies and Cellular Therapy
Melanoma and Advanced Skin Cancers
Pediatric Cancers
Prostate and Urologic Cancers
Sarcoma
Thoracic Cancer

Cancer Therapies
Immunotherapy
Molecular Tumor Board

Supportive Care

Supportive Care and Survivorship Center

Research

Cancer Registry
Clinical Trials
Research Programs
Shared Resources

Education and Training

Office of Cancer Research Training and Education Coordination

About DCI

DCI Overview
DCI Members
Nursing
Careers
Community Outreach, Engagement, and Equity
Office of Equity, Diversity, and Inclusion
Contact
DCI blog
Events

Get Involved

Giving Opportunities
Benefits and Special Events
Breakthroughs Magazine

Make an Appointment

Blogs

Recurrent GBM Brain Tumors with Few Mutations Respond Best to Immunotherapy

Published

January 13, 2021

Written By

Sarah Avery

Director, Duke Health News Office

Topics

Brain Cancer
Preston Robert Tisch Brain Tumor Center
Research

Share

Share This Page

Print Page Or Copy Link Url

Copied to clipboard

Related News

Integrated Proteogenomic Characterization of Glioblastoma Evolution: Overcoming Barriers to Develop Personalized Treatment Strategies

March 19, 2025

ASCO Daily News

Gerald Arthur Grant

Gerald Arthur Grant

Grant Joins the American Board of Neurological Surgery

February 11, 2025

Duke Neurosurgery

Related News

Integrated Proteogenomic Characterization of Glioblastoma Evolution: Overcoming Barriers to Develop Personalized Treatment Strategies

March 19, 2025

ASCO Daily News

Gerald Arthur Grant

Gerald Arthur Grant

Grant Joins the American Board of Neurological Surgery

February 11, 2025

Duke Neurosurgery

Website Privacy Policy
Sitemap
Duke Health Anti-Racism Pledge
Notice on Nondiscrimination
Notice of Privacy Practices
Terms and Conditions
Accessibility
© DUKE CANCER INSTITUTE 2025

Back to Top